AI Article Synopsis
- Mucormycosis is a severe fungal infection that poses a high mortality risk, particularly in children undergoing cancer treatment and those with weakened immune systems.
- A study analyzed 11 pediatric cases from 1991 to 2011 across seven oncology wards in France, identifying Lichtheimia corymbifera and Mucor spp. as the main pathogens.
- Treatment involved antifungal medications, addressing risk factors, and surgical procedures, ultimately achieving cures in 8 of the 11 severe cases.
Article Abstract
Mucormycosis has emerged as an increasingly important infection in oncology centres with high mortality, especially in severely immunocompromised patients. We carried out a retrospective study of 11 children with mucormycosis treated in seven French oncology-haematology paediatric wards during the period from 1991 to 2011. Lichtheimia corymbifera and Mucor spp. were the predominant pathogens. Treatment regimens included antifungal therapy, reversal of underlying predisposing risk factors and surgical debridement. Although mucormycosis is associated with high mortality, this infection could be cured in eight of our cases of severely immunocompromised paediatric cancer patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/myc.12010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!